Hustler Words – A significant shift is underway in the artificial intelligence landscape as Miles Wang, a prominent researcher from OpenAI, is reportedly departing the ChatGPT creator to establish an ambitious new venture focused on leveraging AI for groundbreaking drug discovery. Sources familiar with the plans indicate that Wang, whose prior work at OpenAI centered on accelerating scientific and biological breakthroughs through AI, is poised to lead a startup that could command a staggering $2 billion valuation.
The nascent company is currently in advanced discussions to secure approximately $200 million in seed funding. Industry giant Lightspeed is reportedly in talks to spearhead this crucial investment round, though details remain fluid and the deal is not yet finalized. While Wang has contested specific figures regarding the funding and the precise description of his new enterprise, he has not offered alternative details. Lightspeed has not yet responded to inquiries regarding the potential investment.
This development underscores a burgeoning investor appetite for AI’s transformative potential within the life sciences sector. The market has recently witnessed substantial activity, with Chai Discovery, a two-year-old firm specializing in AI models for predicting molecular interactions in drug identification, announcing a $400 million raise at a $3.8 billion valuation earlier this week. Notably, Chai Discovery’s co-founder, Josh Meier, also has roots as an OpenAI researcher. Furthermore, Isomorphic Labs, a Google DeepMind spin-out dedicated to AI-driven drug discovery, successfully closed a $2.1 billion Series B round in May.
Related Post
According to insights gathered by Hustler Words, Wang’s new startup may initially concentrate on developing AI models capable of identifying novel applications for existing pharmaceuticals or even resurrecting drugs that previously failed in clinical trials. This strategic approach could significantly shorten the path to market and revenue generation, as these compounds have already undergone rigorous safety assessments and received FDA approval.
Wang’s journey to this pivotal moment began in 2024 when he joined OpenAI after opting to leave Harvard University, where he was pursuing a bachelor’s degree in computer science. His tenure at OpenAI saw him co-authoring influential research papers, particularly those exploring how advanced AI models can automate and expedite the process of scientific discovery. His rapid ascent and the substantial backing he’s attracting highlight a growing trend among investors to support young, visionary founders, even those who haven’t completed traditional academic paths.
Leave a Comment